Radiation Therapy in the Management of Diffuse Large B-Cell Lymphoma: Still Relevant?
Radiation Therapy in the Management of Diffuse Large B-Cell Lymphoma: Still Relevant?
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States, comprising approximately 30% to 40% of cases. Currently, the World Health Organization recognizes multiple entities with distinct clinical or pathological features that were previously identified nonspecifically as DLBCL, including primary mediastinal DLBCL and T-cell/histiocyte-rich B-cell lymphoma. Furthermore, gene expression microarray or immunohistochemistry analyses can identify distinct subtypes of DLBCL (eg, germinal center B-cell–like, activated B-cell–like, etc), which have prognostic relevance.[2,3]
Historically, radiation therapy (RT) was the primary treatment for patients with localized DLBCL. Several randomized trials conducted in the 1970s demonstrated that the addition of chemotherapy, primarily CVP (cyclophosphamide, vincristine, prednisone), to RT significantly decreased the risk of relapse for patients with stage I-II disease (Table 1).[4-7] Outcomes were further improved by the addition of anthracyclines. The major advance in systemic therapy in the last two decades, however, has been the introduction of the anti-CD20 antibody rituximab.[8,9] The addition of rituximab to a variety of combination chemotherapy programs significantly improves outcomes, such that R-CHOP (rituximab plus cyclophosphamide, adriamycin, vincristine, prednisone) has now become the systemic therapy of choice for both localized and advanced disease.
The rationale for consolidation RT for both localized and advanced disease is based on the observation that the majority of patients who relapse after receiving chemotherapy alone for DLBCL fail at originally involved sites. Multiple randomized trials have shown that consolidation RT decreases the risk of relapse and improves clinical outcomes. This benefit has been observed in both localized and advanced disease but is sometimes obscured by the peculiarities and complexities of the individual studies. This review endeavors to clarify the role of RT in the current management of patients with DLBCL by critically evaluating and putting into context the individual studies.
Stage I-II Disease
Historically, RT alone was the treatment of choice for localized DLBCL, producing complete response rates of 85% to 95% and long-term freedom from relapse in 30% to 55% of patients.[6,7,10,11] Patients with stage I disease fared considerably better than patients with stage II disease.[10,12] Adjuvant chemotherapy was added in an attempt to improve these outcomes, with positive results—first for the combination of CVP, then for the addition of anthracyclines to the CVP program (Table 1).
After improved outcomes were seen with the combination of chemotherapy and RT for localized disease, the question was raised whether chemotherapy alone would be sufficient. Studies were carried out comparing combination chemotherapy with and without RT. Five randomized trials have now addressed this question (Table 2). All of these studies antedate the use of rituximab and the widespread use of functional imaging.
The optimal study design to assess the value of consolidation RT would be to randomly assign patients to RT or observation after receipt of the same chemotherapy regimen. Two of the above trials used this strategy (Eastern Cooperative Oncology Group [ECOG] 1484 and Group d’tude des Lymphomas de l’Adulte [GELA] LNH 93-4). Three of the trials evaluated whether RT would allow for fewer cycles of chemotherapy (Southwest Oncology Group [SWOG] 8736 and International Extranodal Lymphoma Study Group [IELSG] 4) or less intense chemotherapy (GELA 93-1). These studies are more difficult to interpret because the randomization scheme has two variables in the experimental arm—the addition of RT and the subtraction of some chemotherapy.
This study enrolled patients with early-stage (bulky stage I, IE, or II), diffuse aggressive lymphomas; DLBCL constituted 80% of cases. Of the 352 eligible patients, 68% had stage II disease and 31% had disease larger than 10 cm—a population with a more unfavorable prognosis compared with the those of the SWOG and GELA 93-4 studies discussed below. All patients received 8 cycles of CHOP. If a complete response was achieved (as assessed by CT imaging), patients were randomly assigned to either consolidation RT (30 Gy) or observation. All patients who achieved a partial response received RT to a somewhat higher dose (40 Gy). The primary endpoint was disease-free survival; the study was powered to detect a 20% improvement at 2 years in patients who received RT after achieving a complete response with chemotherapy.
The addition of consolidation RT in patients who achieved a complete response to CHOP was associated with improved disease-free survival (Figure 1). Disease-free survival at 6 years was 73% with consolidation RT versus 56% with observation (P = .05). Crude rates of local failure were 4% with consolidation RT vs 16% with observation (P = .06). While short-term survival was statistically improved with consolidation RT, with longer follow-up (and smaller numbers of patients at risk) that benefit diminished. Overall survival at 5, 10, and 15 years was 87%, 68%, and 60% with consolidation RT vs 73%, 65%, and 44% with observation (P = .24).
Of the patients with a partial response after chemotherapy, 31% converted to a complete response with RT. Disease-free survival in patients who received RT (40 Gy) after achieving a partial response to chemotherapy was ~60% at 6 years. These excellent results in partial-response patients may reflect the efficacy of consolidation RT as well as the limitations of CT imaging to assess response to chemotherapy.
GELA LNH 93-4
This study enrolled older patients (aged 60 years or older) with early-stage aggressive non-Hodgkin lymphoma (80% DLBCL) without risk factors such as elevated lactate dehydrogenase level or poor performance status. Patients (n=576) were randomly assigned to receive either 4 cycles of CHOP or 4 cycles of CHOP plus consolidation RT (40 Gy). The median age was 68, and 65% had stage I disease. The primary endpoint was event-free survival, and the study was powered to detect a 10% improvement at 2 years.
With a median follow-up of 7 years, there was no difference in event-free survival (61% vs 64%, P = .6) (Figure 2) or overall survival (72% vs 68%, P = .5) between patients receiving consolidation RT and those not receiving it. Crude rates of local failure were lower in patients who received RT (7% vs 18%).
This study evaluated whether the addition of consolidation RT would allow for fewer cycles of chemotherapy. Patients with intermediate- or high-grade non-Hodgkin lymphoma (75% DLBCL) with stage I or non-bulky (smaller than 10 cm) stage II disease were eligible. Patients were randomly assigned to receive either 8 cycles of CHOP or 3 cycles of CHOP plus consolidation RT (40 to 55 Gy, depending on response to chemotherapy). Among the 401 eligible patients, 67% had stage I disease.
As expected, life-threatening toxicity, primarily neutropenia and decreased left ventricular function, was higher among patients who received 8 cycles of CHOP (40% vs 30%, P = .06). When the study was initially published, the combination of 3 cycles of CHOP plus consolidation RT was associated with improved 5-year progression-free survival (77% vs 64%, P = .03) (Figure 3) and overall survival (82% vs 72%, P = .02). With longer follow-up, 5-year overall survival remained significantly different (82% vs 74%), but mortality related to relapse between years 5 and 10 was increased in the CHOP × 3 plus RT group. These late relapses negated the initial improvement in outcomes. These later results have only been reported in abstract form, necessitating caution in interpreting the “final” results of this study. Nevertheless, the SWOG update suggests that a limited number of chemotherapy cycles may be inadequate to control systemic disease long term in some early-stage patients.
This study enrolled younger patients (no older than 61 years) with stage I-II aggressive non-Hodgkin lymphoma (81% DLBCL) without risk factors. Patients were randomly assigned to receive either an aggressive induction chemotherapy regimen (3 cycles of ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone] followed by consolidation chemotherapy consisting of methotrexate, etoposide, ifosfamide and cytarabine) or 3 cycles of CHOP and consolidation RT (40 Gy). The primary endpoint of the study was 2-year event-free survival; the study was powered to detect an absolute improvement of 10% with intense chemotherapy without RT.
Although a complete response occurred in ~93% of patients in both groups, event-free survival was better in the intensive chemotherapy arm. Five-year estimates were 82% in the intense chemotherapy arm vs 74% with CHOP plus RT (P < .01) (Figure 4). Five-year survival was also better in the intense chemotherapy arm (90% vs 81%, P = .001). The proportion of first failures that included originally involved sites was lower in the patients receiving RT (28% vs 62%). It is also of interest that the total number of relapses in the intense chemotherapy arm comprised 13% of the patients in that group (42/318), while the number of relapses in non-irradiated sites in the CHOP plus RT arm involved 17% of the patients in that group (56/329)—again pointing toward a failure of limited chemotherapy to control systemic disease.
As with the SWOG study, the intensive chemotherapy arm experienced greater toxicity, with grade III infection in 11% of patients—compared with 1% of patients in the CHOP plus RT arm. Because of the substantial toxicity seen with the intense chemotherapy regimen, this program has not been widely adopted. In addition, it is likely that 3 cycles of CHOP is inadequate therapy; outcomes might have been better with 4 to 6 cycles of CHOP plus RT.
IELSG 4 (Gastric DLBCL)
This multicenter study, reported by Martinelli and colleagues, enrolled patients with high-grade non-Hodgkin lymphoma of the stomach (stage I-II) who achieved a complete response as assessed by CT and endoscopy after an anthracycline-containing regimen. Patients who achieved a complete response after 4 cycles of chemotherapy were randomly assigned to receive either consolidation RT (minimum of 30 Gy) or 2 additional cycles of chemotherapy. Patients with a partial response after 4 cycles received an additional 2 cycles of chemotherapy, and if they then achieved a complete response, they were randomly assigned to either radiation or observation. The primary endpoint was 2-year disease-free survival; the study was powered to detect a 30% improvement with RT. Due to poor accrual, the study was closed after 55 of a planned 125 patients had been enrolled.
Consolidation RT was well tolerated without major complications. Four patients in the chemotherapy-alone arm experienced failure (3 local failures and 1 distant failure); however, there were no failures after consolidation RT, resulting in a disease-free survival of 100% with RT—compared with 82% in patients without RT (P = .04) (Figure 5). There was no difference in overall survival.
Taken together, these studies support the following conclusions:
• Consolidation RT decreases the risk of relapse at treated sites and hence the overall risk of relapse.
• For adequate systemic control, more than 3 cycles of CHOP (or R-CHOP) are probably required, except in the most favorable cases.
• Increasingly effective systemic therapies may decrease the absolute benefit of consolidation RT, but possibly at the expense of increased toxicity.
• Older patients, especially those whose disease has a favorable prognosis and/or who have serious medical comorbidities, may derive less benefit from consolidation RT than younger patients.
The addition of the anti-CD20 antibody rituximab has improved the efficacy of systemic therapy and improves survival in DLBCL.[8, 9] There have been no randomized studies evaluating the role of consolidation RT when rituximab is also administered. In a phase II SWOG study, patients with aggressive non-Hodgkin lymphoma with at least one adverse risk factor were treated with 3 cycles of R-CHOP plus involved-field RT. Progression-free survival was excellent (88% at 4 years). A matched population from the previous SWOG study of 3 cycles of CHOP plus involved-field RT had a progression-free survival of 78%, suggesting superiority of R-CHOP plus consolidation RT. Whether the addition of rituximab increases the absolute benefit of RT (by decreasing the risk of systemic failure) or decreases the absolute benefit of RT (by decreasing the risk of local failure) is unknown, given the lack of randomized trials.
A retrospective study from M.D. Anderson evaluated 469 patients with both localized and advanced disease who were treated with a rituximab-containing chemotherapy regimen (R-CHOP in 70%). Consolidation RT was used at the discretion of the treating physicians. On multivariate analysis, consolidation RT improved both progression-free and overall survival. This benefit was observed for both localized and advanced disease and for bulky and non-bulky presentations.
Positron Emission Tomography (PET)
Functional imaging,18-fluorine fluorodeoxyglucose PET in particular, is now commonly used before, during, and/or after chemotherapy to stage and assess response. How to incorporate PET-assessed response into the treatment algorithm of DLBCL is unclear. Furthermore, interpretation of PET is subjective, with significant inter- and intra-observer variability. One should exercise caution when changing a planned treatment protocol because of an unexpected finding on PET.
With these caveats, a complete response as assessed by PET represents a good systemic response to chemotherapy— but it does not necessarily mean all cancer has been eradicated. Indeed, a negative PET response probably represents 1 to 2 logs of additional cell kill beyond a complete response as assessed by CT. A negative PET response is often mistakenly interpreted to mean that consolidation RT is unnecessary. On the contrary, if chemotherapy has more effectively eradicated systemic disease, the potential benefit of further local therapy increases (until systemic therapy is so effective that both microscopic systemic disease and macroscopic local disease are completely eradicated and relapse rates approach 0%—a situation that has not yet been realized).
Numerous studies have shown that an incomplete response as assessed by PET is associated with an increased risk of failure, particularly in the setting of chemotherapy alone,[21-23] but also with combined modality regimens. Treatment escalation is often necessary, either with salvage chemotherapy with autologous stem cell transplantation or with full-dose RT (discussed later), depending on the individual circumstances. It is usually advisable to repeat a biopsy before escalating therapy, particularly with a stem cell transplant, given the subjective nature of PET interpretation.
Summary and Recommendations: Stage I-II DLBCL
Until further studies have been completed, we recommend consolidation RT, typically 30 Gy, in most patients with localized DLBCL who achieve a complete response, as assessed by PET, to R-CHOP or similar regimens. Involved-field RT, up to 30 Gy, for DLBCL is generally well tolerated with a relatively low risk of late toxicity, including secondary malignancies.[25, 26] Improved technology, such as intensity-modulated RT, can be particularly helpful in avoiding critical structures and minimizing late morbidity (eg, the parotid gland can be spared when treating cervical lymph nodes).